The role of neutralizing antibodies in prevention of HIV-1 infection: what can we learn from the mother-to-child transmission context?

Martine Braibant, Francis Barin

To cite this version:
Martine Braibant, Francis Barin. The role of neutralizing antibodies in prevention of HIV-1 infection: what can we learn from the mother-to-child transmission context?. Retrovirology, BioMed Central, 2013, 10 (1), pp.103. 10.1186/1742-4690-10-103. inserm-00872427

HAL Id: inserm-00872427
https://www.hal.inserm.fr/inserm-00872427
Submitted on 12 Oct 2013

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
The role of neutralizing antibodies in prevention of HIV-1 infection: what can we learn from the mother-to-child transmission context?

Martine Braibant1* and Francis Barin1,2

Abstract

In most viral infections, protection through existing vaccines is linked to the presence of vaccine-induced neutralizing antibodies (NAbs). However, more than 30 years after the identification of AIDS, the design of an immunogen able to induce antibodies that would neutralize the highly diverse HIV-1 variants remains one of the most puzzling challenges of the human microbiology. The role of antibodies in protection against HIV-1 can be studied in a natural situation that is the mother-to-child transmission (MTCT) context. Indeed, at least at the end of pregnancy, maternal antibodies of the IgG class are passively transferred to the fetus protecting the neonate from new infections during the first weeks or months of life. During the last few years, strong data, presented in this review, have suggested that some NAbs might confer protection toward neonatal HIV-1 infection. In cases of transmission, it has been shown that the viral population that is transmitted from the mother to the infant is usually homogeneous, genetically restricted and resistant to the maternal HIV-1-specific antibodies. Although the breath of neutralization was not associated with protection, it has not been excluded that NAbs toward specific HIV-1 strains might be associated with a lower rate of MTCT. A better identification of the antibody specificities that could mediate protection toward MTCT of HIV-1 would provide important insights into the antibody responses that would be useful for vaccine development. The most convincing data suggesting that NAbs might confer protection against HIV-1 infection have been obtained by experiments of passive immunization of newborn macaques with the first generation of human monoclonal broadly neutralizing antibodies (HuMoNAbs). However, these studies, which included only a few selected subtype B challenge viruses, provide data limited to protection against a very restricted number of isolates and therefore have limitations in addressing the hypervariability of HIV-1. The recent identification of highly potent second-generation cross-clade HuMoNAbs provides a new opportunity to evaluate the efficacy of passive immunization to prevent MTCT of HIV-1.

Keywords: HIV-1, Neutralizing antibodies, Mother-to-child transmission, Preventive vaccine, Passive immunization, Immunoprophylaxis

Review

Introduction

UNAIDS estimates that there were 34.0 million people living with the human immunodeficiency virus (HIV) at the end of 2011. The development of a safe, effective, preventive HIV vaccine remains among the highest global health priorities. Most vaccines that successfully control viral diseases induce the production of neutralizing antibodies (NAbs) that prevent infection. In the case of HIV-1, a key element for NAbs to be effective in preventing infection is their capacity to neutralize the highly diverse circulating HIV-1 variants, which can differ by more than 30% in the sequences of their envelope glycoproteins. Encouragement for the development of a NAb-based anti-HIV-1 vaccine was provided by successful passive immunization studies in macaque models showing that broadly human monoclonal NAbs administered orally, vaginally or intravenously could prevent the acquisition of infection [1-10]. Despite the fact that in some of these experiments, the viral strain used for
challenge was particularly sensitive to neutralization by the passively administered NAb s, these results provided the proof-of-concept that antibodies can block HIV-1 infection. Unfortunately, the capability of vaccine candidates to induce NAb s has turned out to be extremely complex and disappointing. First attempts to develop antibody-based anti-HIV-1 vaccines in man involved recombinant protein immunogens based on monomeric forms of the surface-exposed gp120 component of the envelope glycoprotein (AIDSVAX gp120 B/B and B/E) [11-13]. High levels of antigen-specific antibodies were induced in human vaccinees but failed to neutralize most primary isolates and did not confer protection [14-17]. More recently, the RV144 vaccine trial based on a prime-boost regimen consisting of a recombinant canarypox vector prime (ALVAC-HIV) and gp120 protein boost (AIDSVAX gp120 B/E), showed only moderate protection in low-incidence heterosexuals [18]. These trials, in a real life situation, have indicated the limitations of animal model studies that used only a few selected challenge viral strains. They also highlighted the probable need to develop more sophisticated envelope immunogens. For this, lessons from studies aiming at dissecting the antibody response during natural infection might be particularly useful. It has been shown recently that broadly NAb s, developed after several years of infection by some HIV-1 infected patients, require a high level a somatic mutations to become broad and potent [19-24]. This suggests that an effective vaccine may require a combination of various envelopes to direct B-cell responses through multiple rounds of antibody maturation and mutation process [25]. Another key question for vaccine development is the identification of correlates of protection. Indeed, the specificity and magnitude of the NAb s response required to confer protection against HIV-1 transmission in humans are still unclear, and progress in this field is a key step on the road to an effective HIV-1 vaccine.

Mother-to-child transmission: a model to identify correlates of protection

Mother-to-child transmission (MTCT) of HIV-1 is currently the principal cause of HIV infections in children. Whereas access of HIV pregnant women to antiretroviral therapy has increased significantly, HIV infection in children remains a major concern. In 2011, an estimated 330,000 children were newly infected with HIV (UNAIDS). Without any antiretroviral treatment, MTCT rate of HIV-1 is around 30 to 40% and occurs mainly at three stages: in utero during pregnancy (5-10%), perinatally at the time of labor and delivery (15-20%), and postpartum through breastfeeding (10-15%) [26-29] (Figure 1). This contrasts with a much lower rate of MTCT of HIV-2 which, in absence of antiretroviral treatment, ranges from 0% to 4% only [30-34]. Despite the high transmission rates of HIV-1, a large number of children exposed to HIV-1 do not become infected. Several maternal factors, including low CD4+ T-cells counts and high viral loads are associated with an increasing risk of HIV-1 MTCT [35]. The lower plasma viral load in HIV-2 infected patients, compared to HIV-1 infected patients, may account for the lower MTCT risk for HIV-2 [33,34,36-40].

The role of maternal immune response in limiting HIV-1 transmission to the infant is still unclear. The placenta is relatively impermeable to IgA and IgM, levels of which are therefore very low in the newborn. In contrast, maternal IgG are transported over the placenta by an active process mediated by the FcRn receptor [41]. The timing of maternal IgG passage across the placenta during pregnancy was addressed in several studies (for a review see [42]). During the first trimester, very little IgG is transmitted to the fetus, but in the second trimester, the fetal IgG concentration increases from approximately 10% of the maternal concentration at 17–22 weeks of gestation to 50% at 28–32 weeks [41,43-45]. During the third trimester, fetal IgG levels continue to rise, reaching normal or somewhat exceeding adult levels at term [45-50] (Figure 1). It was illustrated recently in the HIV-1 context in a study that showed that the envelope binding antibody titers were strongly correlated and similar between mothers and their corresponding infants [51]. MTCT constitutes therefore an attractive model to explore the putative protecting role of passively acquired HIV-specific IgG

![Figure 1 Infant antibody levels over the three possible stages (in utero, perinatally or postpartum) of mother-to-child transmission of HIV-1. During pregnancy, maternal IgG are transmitted to the fetus across the placenta, reaching normal or somewhat exceeding adult levels at term. After birth, the IgG transferred from the mother disappear progressively, while the amount of IgG being produced by the infant continues to increase. In contrast, the placenta is relatively impermeable to Ig of other classes, levels of which are therefore very low in the newborn.](image-url)
against HIV acquisition. In the absence of data on the pu-
tative role of NAb in prevention of MTCT of HIV-2, this
review will focus on HIV-1 infection that has been the
subject of intensive investigations.

Selective transmission of HIV-1 variants from mothers to
infants
The first molecular studies of env sequences diversity is-
sued from infected individuals, adults as well as children,
have shown that most of acute/recent infections are
characterized by the presence of a highly homogenous
-genetically-restricted virus population in contrast to the
-high genetic diversity observed several years later at time
-of chronic infection [52-62]. These observations led
rapidly to the assumption of a substantial bottleneck in
virus transmission (Figure 2A). Recently, the use of sin-
gle genome amplification (SGA) of HIV-1 plasma viral
RNA obtained from acutely infected adult individuals,
allowed the identification of transmitted/early founder
viruses, and the precise estimation of their diversity
[63-67]. These studies showed evidence of infection by a
single virus in ~80% of heterosexuals and ~60% of HIV-
infected men who have sex with men [63,64,66,67]. In
contrast, the frequency of multiple variants transmission
was found to be higher among intravenous (IV) drug
users (~60%), including one subject who was infected by
at least 16 variants [65]. The high frequency of multiplevi-
ants transmission in IV drug users could be due to
the absence of a mucosal barrier to virus transmission
and higher virus inocula. To date, such large studies
have not been conducted on samples from children
born to infected mothers. However this question has
been considered using different molecular approaches
(Table 1) (Figure 2B) [61,68-89]. Data vary from one
study to another but all together, comparing the viral
population in mother-child pairs, they showed a homo-
genous genetically-restricted population in the major-
ity of infected infants (156 of 235; table I), suggesting a
selective transmission of some viral variants during
MTCT (Figure 2B). The lack of consensus among these
studies may be due to the fact that many studies com-
pared only a limited number of mother-child pairs and
did not address the route of transmission (in utero, peri-
natally or postpartum through early breastfeeding). In

Figure 2 Selective transmission of HIV-1. A. The quasispecies of the chronically infected donor is usually composed of a major viral population
(dark blue virions), as well as numerous other minor variants. One of these minor variants (yellow virion) successfully crosses the mucosal barrier
to generate the infection of the recipient. B. The neighbor-joining trees of HIV-1 env gp120 nucleotide sequences issued from two mother-infant
pairs show the transmission of a single maternal viral variant [85]. Bootstrap values are expressed as percentages per 1000 replicates. Only
bootstrap values >50% are indicated. Horizontal branch lengths are drawn to scale, with the black bar denoting 1% divergence. Each symbol
denotes a single env sequence; □, maternal sequence; ●, infant sequence.
addition, the ages of the infants at time of sample collection varied considerably among studies. Focusing on transmission through breastfeeding, three recent studies have shown that there is no or very limited viral compartmentalization between milk and blood, suggesting that breast milk viruses are typical of circulating viruses [90-92]. As with other routes of MTCT, a genetic bottleneck that restrict the number of variants transmitted through breastfeeding to a single or a small number of variants was reported [82]. Several studies examined the molecular characteristics of the envelope glycoproteins of transmitted viruses that might explain the selective process. Two studies of Wolinky's group, in which MTCT route was not defined, reported that the potential N-linked glycosylation site (PNGS) proximal to the first cysteine of the V3 loop (N295) was strikingly absent from the infant’s sequence populations but present in the majority of the maternal sequence sets [61,68]. This observation has not been found by other investigators [69,70,73,74]. Studies performed on sequences encoding the full-length gp120 reported shorter variable regions and/or fewer PNGS in clade A and C viruses transmitted from mother-to-infant, mainly perinatally or early postpartum [81,86,88]. In contrast, we and others did not find altered gp120 length or PNGS number in the clade B and CRF01-AE viruses transmitted perinatally from mothers to their infants [85,87]. Similarly, we and others did not find shorter gp120s or fewer PNGS in maternally transmitted CRF01-AE viruses, we however found a limited number of PNGS, N301 in V3 and

### Table 1: Studies of the viral population of HIV-1 infected infants

| Nature          | Infant samples               | Amplified env region | Infection route | Homo-/heterogeneous population ratio | References |
|-----------------|------------------------------|----------------------|----------------|-------------------------------------|------------|
| PBMCs           | 2 to 4 months                | V3 and V4-V5         | Unspecified    | 3/0                                 | [61]       |
| PBMCs           | Unspecified                  | V3 and V4-V5         | Unspecified    | 4/0                                 | [68]       |
| PBMCs and serum | 0 to 4 months                | V3                   | 1 IU, 9 unknown| 8 (1 IU)/2                           | [69]       |
| Serum           | At birth                     | V3                   | 1 IU           | 1/0                                 | [70]       |
| PBMCs           | 0 to 12.5 months             | V3                   | 1 IU, 4 unknown| 2/3 (1 IU)                          | [71]       |
| PBMCs           | 2 days to 7 weeks            | V1-V2-C2             | Unspecified    | 1/2                                 | [72]       |
| PBMCs           | 1 week to 34 months          | V3                   | Unspecified    | 7/0                                 | [73]       |
| PBMCs           | 5 days to 1.5 months         | V3                   | Probably 1 PN, 3 IU | 1 (PN)/3 (IU) | [74] |
| PBMCs and plasma| 2 to 40 days                 | C2-V3                | Unspecified    | 3/1                                 | [75]       |
| PBMCs           | 1 month                      | V3                   | Unspecified    | 13/4                                | [76]       |
| Plasma          | 48 hours or 2 to 6 weeks     | V3-V5                | 9 PN, 14 IU    | 17 (7 PN, 10 IU)/6 (2 PN, 4 IU)     | [77]       |
| PBMCs           | 0 or 2 to 6 months           | C2-V4                | 3 PN or early PP, 1 IU | 3 (2 PN, 1 IU)/1 | [78] |
| PBMCs           | 0 or 6 weeks                 | V1-V4                | 7 PN or early PP, 6 IU | 6 (2 IU, 4 PN)/7 (4 IU, 3 PN) | [79] |
| PBMCs           | 48 hours or 2 to 6 weeks     | V3-V5                | 7 PN, 14 IU    | 15 (5 PN, 10 IU)/6 (2 PN, 4 IU)     | [80] |
| PBMCs or plasma | 6 weeks                      | V1-V5                | 8 PN or early PP, 1 IU, 3 BF | 11/1 (PN) | [81] |
| PBMCs or cord blood | 0 or 6 to 15 months     | V1-V3                | 3 PP, 1 IU     | 4/0                                 | [82]       |
| PBMCs           | 4 to 18 months               | V1-V5                | Unspecified    | 0/3                                 | [83]       |
| Plasma          | 0 or 6 weeks                 | V1-V2                | 23 PN, 25 IU   | 20 (6 PN, 14 IU)/28 (17 PN, 11 IU)  | [84]       |
| Plasma          | 48 hours or 6 weeks          | V1-V5                | 11 PN, 6 IU    | 14 (9 PN, 5 IU)/3 (2 PN, 1 IU)      | [85]       |
| PBMCs           | 2 to 4 months                | V1-V5                | 6 PN or early PP | 5/1                                 | [86]       |
| Plasma          | 30 to 66 days                | V1-V5                | 5 PN           | 3/2                                 | [87]       |
| Plasma          | 0 or 6 weeks                 | V1-V5                | 9 PN or early PP, 10 IU | 13 (5 PN, 8 IU)/6 (4 PN, 2 IU) | [88] |
| Plasma          | 3 or 6 months                | complete env         | 2 PP           | 2/0                                 | [89]       |

**Table notes:**
- *Time of the first PCR or coculture positive collected sample after birth.
- PN: perinatally; IU: in utero; PP: postpartum through breastfeeding.
Neutralizing antibodies: in search of correlates of protection in the MTCT context

MTCT offers a unique opportunity to explore the putative role of NAbs in restricting or preventing infection, especially when the transmission occurs in presence of high levels of passively acquired maternal IgG, i.e. during the perinatal and early breastfeeding periods. Conflicting results have been obtained concerning the role of maternal NAbs in reducing MTCT of HIV-1. Early studies, each relatively small, showed that non-transmitting mothers had more frequently detected and/or higher titers of autologous NAbs in sera of transmitting and non-transmitting mothers, using panels of heterologous sera [95]. Interestingly, the N-linked glycan at position 301 was recently shown to be important for HIV-1 neutralization by several broad and potent monoclonal NAbs of the PGT series (PGT125-128, PGT130 and PGT131) [96]. Similarly, Moore et al. recently reported in two HIV-1-infected adults the apparition of the N-linked glycan at position 332 targeted by PGT128, through immune escape from earlier strain-specific antibodies [97]. It could be possible that NAbs drive viral selection during MTCT, leading to variants with conserved glycan motifs that would confer a selective advantage.

Because transmitted variants were found to be resistant to neutralization by their own mother’s plasma in several studies, we previously hypothesized that protective antibodies might be those with a broad neutralizing activity. To test this hypothesis, we conducted three large studies in Thailand [107,108], and one study in French patients [109], in which we compared the breadth and levels of NAb in sera of transmitting and non-transmitting mothers, using panels of heterologous primary isolates of different clades. Our data did not support an association between the breadth of HIV-1 neutralizing activity and a lower rate of MTCT of HIV-1, whether transmission occurred in utero or perinatally (the infants were not breast-fed). Similar results were obtained by others in Kenyan infants of HIV-1 positive mothers [110]. All these data clearly indicate that infants who acquired broad and potent NAbs able to neutralize heterologous HIV-1 variants of different subtypes from their mothers did not show a reduced risk of infection. However, our studies suggested that particular HIV-1 variants might be indicators of NAbs associated with in vivo protection. Indeed we found that NAbs toward a CRF01-AE isolate, MBA, were significantly associated with a lower rate of MTCT in Thailand. Similarly, statistically significant higher frequencies or titers of NAbs toward several strains were observed in non-transmitting mothers in our French study when the clade B-infected mothers or non clade-B-infected mothers were analyzed separately [109]. Collectively, these data suggest that particular HIV-1 variants may provide a measure of protective antibodies depending on the population. These HIV-1 variants may be particular strains on which epitopes targeted by protective NAbs would be particularly well exposed in contrast to those of non-protective antibodies. The identification of these strains would be dependent of the HIV-1 subtype of the studied population suggesting that the neutralizing response specificities might vary between viral subtypes. Conducting large studies on homogeneous populations (in terms of geographical origin, viral clade, maternal viral loads and antiretroviral prophylaxis) to limit confounding viral and/or host factors would be necessary to identify such indicator strains.

The targeted epitope(s) of the neutralizing response associated with protection was not explored in studies cited above. To date, only one recent study conducted in a cohort of South African patients addressed this question by focusing on the putative role of maternal gp41-specific antibodies passively transferred to newborns [111]. An association of antibodies to the membrane-proximal external region (MPER) of gp41 with virus neutralization and protection was reported. This observation needs to be confirmed by other studies. More particularly it should be extended to other important conserved epitopes using various techniques, such as serum absorption with recombinant Env proteins or functional neutralization assay with various Env-pseudotyped viruses, that have been recently developed to dissect the neutralizing activity present in human sera [112-114]. These epitopes, most of them being of conformational nature, were identified thanks to the isolation of human monoclonal broadly neutralizing antibodies (HuMoNAb) [96,115-118] (Figure 3). They are conserved regions of the HIV-1 envelope glycoprotein such as the CD4 binding site (CD4bs) on gp120, quaternary structure dependent epitopes on the V1-V2 variable loops of gp120, glycan-dependent epitopes involving the V3 region of gp120, and the MPER of gp41. A fine
comparison of the specificity of the neutralizing response between transmitting and non-transmitting mothers by such extensive serum mapping using Env proteins or Env-pseudotyped viruses derived from HIV-1 strains indicator of protective antibodies should help to define more precisely if some antibody specificities correlate with protection in the MTCT context.

In the absence of antiretroviral prophylaxis, HIV is transmitted via breastfeeding to only 10-15% of infants, despite daily milk exposure. This suggests that breast milk may contain antiviral immune factors protecting most infants from mucosal HIV infections. HIV-1 envelope-specific antibody responses have been detected in milk. However, despite a predominance of secretory IgA in milk, the magnitude of the HIV-1 envelope-specific IgA activity is lower than that of envelope-specific IgG activity [119-122]. Similarly, the predominant SIV envelope-specific antibodies in milk from lactating rhesus monkeys are of the IgG isotype [123]. This is in accordance with what has been observed in other mucosal compartments, such as genital tract and saliva [119,120,124-128]. A few studies explored the putative role of envelope-specific antibodies present in breast milk of infected mothers to prevent infant infection. Quantitative studies of HIV or SIV envelope-specific binding antibodies did not reveal any difference between transmitting and non-transmitting mothers [129-131]. However, the neutralizing activity of these antibodies was not analyzed in these studies. Two recent studies made extensive comparisons of the neutralizing and antibody-dependent cellular cytotoxicity (ADCC) responses in breast milk and plasma from African HIV-infected lactating women [122,132]. Although lower in magnitude, the neutralizing and ADCC activities in milk were directly correlated with those in plasma and were primarily mediated by plasma-derived IgG antibodies. Similarly, SIV-specific IgA antibodies had limited neutralization potency compared to SIV-specific IgG in SIV-infected rhesus monkeys [123]. This suggests that IgA-mediated neutralizing and ADCC responses did not play a major role in preventing MTCT transmission via breastfeeding. However, the capacity of milk IgA to block HIV-1 transcytosis across epithelial cells was not studied. Such a protective role, recently reported for preventing vaginal and rectal infections in animal models, cannot be excluded [133,134]. The preventing role of IgG responses in mothers’ milk is difficult to explore due to the presence in newborns of high physiological levels of passively acquired maternal IgG. One study reported a higher magnitude of milk IgG-mediated ADCC in HIV-1-infected women who did not transmit HIV to their infants postnatally than in transmitters [132]. This suggests that an efficient vaccine should be able to induce a protective humoral response that could be transferred also through breastfeeding.

Studies of passive immunization in newborn macaques: sterilizing immunity

The development of MTCT models of SIV infection in macaques has been very useful to evaluate the potential of passively transferred antibodies to prevent infection.
A first attempt of passive immunization of newborn rhesus macaques with pooled sera from chronically SIV-infected rhesus macaques has been shown to be protective from oral SIV exposure that mimics the mucosal exposure occurring during perinatal and breast-milk HIV-1 transmission (Table 2) [1]. However, the precise mechanism for the protection could not be established as no neutralizing activity of these pooled sera could be detected in vitro against the challenge virus. At about the same time, the first HuMoNAbs, F105, 2F5, 4E10, 2G12 and b12, were generated and characterized (Figure 3). F105 and b12 are directed against the CD4 binding site of gp120 [135,136], 2G12 recognizes a conformational carbohydrate-dependent epitope on gp120 [137], and 2F5 and 4E10 are directed against the MPER of gp41 [138,139]. To evaluate the capacity of these HuMoNAbs to prevent HIV-1 infection, chimeric simian-human immunodeficiency viruses (SHIV) were used. Because the SIV and HIV envelope glycoproteins are too divergent to analyze their sensitivity to NAbs, SHIV were constructed based on a SIV backbone in which the SIV env gene was replaced by an HIV-1 env gene. The first SHIV constructs expressed the env gene of the T-cell line laboratory-adapted (TCLA) HIV strain IIIB which is highly neutralization-sensitive [140-143], but constructs using env genes from primary HIV-1 isolates were subsequently made, generating more pathogenic and more neutralization-resistant SHIV viruses [144-147]. Using the SHIV-macaque model, several studies have shown that passive administration of high concentrations of various

Table 2: Studies of passive immunization in newborn macaques

| Antibody (Route, Concentration) | Treatment | Infusion timing | Challenge Virus | Route | Sterile protection | References |
|--------------------------------|-----------|----------------|-----------------|-------|--------------------|------------|
| SIV hyperimmune serum (SC, 20 mL/kg) | - Postnatal: 2 days before challenge and 5 and 12 days after challenge | SIVmac 251 (10^5 TCID50) Oral | - 2/2 | 1 |
| - HIV immune globin (HIVIG) (IV, 400 mg/kg) | - Postnatal: 3 weeks after challenge | | - 0/3 | 2 |
| - 2F5 (IV, 15 mg/kg) | | SHIV89.6PD (40 TCID50) IV | - 0/3 | 3 |
| - 2G12 (IV, 15 mg/kg) | | | - 0/3 | 3 |
| - 2F5 / 2G12 (IV, 15 mg/kg of each) | Postnatal: 24 hours before challenge | | - 0/3 | 3 |
| - HIVIG/2F5/2G12 (IV, 400 mg/kg of HIVIG, 15 mg/kg of each HuMoNAbs) | | SHIV-89.6P (15 AID50) Oral | - 3/6 | 4 |
| - F105/2G12/2F5 (IV, 10 mg/kg of each) | Pre- and postnatal: 1–4 hours before and 8 days after challenge | SHIVIII-vpu+ (10 AID50) Oral | - 2/2 | 4 |
| 2G12/b12/2 F5 (IV, 10 mg/kg of each) | Postnatal: 1 hour before and 8 days after challenge | | - 2/2 | 148 |
| F105/2G12/2F5 (IV, 10 mg/kg of each) | Postnatal: 3–4 hours before challenge and 8 days after challenge | SHIVIII-vpu+ (10 AID50) Oral | - 2/2 | 149 |
| 2G12/b12/2F5/4E10 (IV, 30 mg/kg of each except 4E10 at 11.5 mg/kg) | Postnatal: 1 hour and 8 days after challenge | SHIV-89.6P (15 AID50) Oral | 2/4 | 6 |
| 2G12/2F5/4E10 (IM, 40 mg/kg of each) | | | 2/4 | 150 |
| 2G12/b12/2 F5/4E10 (IV, 30 mg/kg of each) | | | 3/4 | 151 |
| - 2G12/2F5/4E10 (IM, 40 mg/kg of each) | | | 1/4 | 151 |

TCID50: 50% tissue culture infectious dose; AID50: 50% animal infectious dose.
SC: subcutaneous; IV: intravenous; IM: intramuscular.
combinations of the first-generation HuMoNAbs protected neonatal rhesus macaques against high-dose intravenous or oral challenge with SHIVs (Table 2) [3,4,6,148-151]. These results provided the proof-of-concept that antibodies can prevent infection. However the current SHIV models, which include only a few HIV Envs, provide data that are limited to protection against a restricted number of isolates and therefore has limitations when considering the high diversity of HIV-1 isolates. In addition, these studies highlighted the importance of the timing of administration, since HuMoNAbs must be present at the time of viral challenge or only a few hours later to prevent the establishment of infection (sterilizing immunity) of the newborn macaques (Table 2) (Figure 4A). There was no protection when antibodies were administered more than 12 hours post-virus inoculation (Figure 4B). Recently, the association of several technological advances allowed the identification of new second-generation HuMoNAbs (particularly the PG, PGT and VRC series) that are tenfold to 100-fold more potent in vitro than the first-generation HuMoNAbs used in passive immunization studies [96,115-117,152,153] (Figure 3). One of these antibodies, PGT121, was able to mediate sterilizing immunity against high-dose mucosal viral challenge in adult rhesus macaques at serum concentrations that were significantly lower than those observed in previous studies [154]. In addition, Klein et al. re-examined the possibility to use antibody transfer as a therapeutic modality [155]. Using a humanized mice model and combinations of these new NAb that target complementary

Figure 4 Studies of passive immunization in newborn macaques. A. Passive administration of high concentrations of various combinations of the first-generation HuMoNAbs (b12, 2G12, 2F5, 4E10, F105) (white arrow) before or simultaneously with intravenous or oral challenge with SHIVs (green arrow) protected neonatal rhesus macaques against infection: there was no infection [4,149,150]. B. There was no protection when the first-generation HuMoNAbs (white arrow) were administered more than 12 hours post-virus inoculation (green arrow) [151]. C. New second-generation HuMoNAbs (PG-, PGT-, VRC-series) that are 10- to 100-fold more potent in vitro than the first-generation HuMoNAbs have been identified [96,115-117,152,153]. It would be interesting to re-evaluate the potential protective potency of NAb in newborn macaques when administered either before or after (white arrow) viral exposure (green arrow).
sites on the HIV-1 spike protein, they showed that these antibodies could effectively control HIV-1 infection and suppress viral load to levels below detection. Given these new data, it would be interesting to evaluate the protective potency of these new NAbs in newborn macaques for both pre-exposure and post-exposure prophylaxies (Figure 4C). Indeed, a recent study of passive administration of neutralizing IgG (including the HuMoNAb b12) at levels insufficient to block infection to newborn macaques before oral challenge with a SHIV virus has shown that immunized macaques rapidly developed NAbs and had a significantly reduced plasma viremia [156]. This supports the use of NAbs to augment B cell responses and viral control in perinatal settings, although further studies are needed to understand the mechanisms underlying their beneficial effects.

Prevention of mother to child transmission: immunoprophylaxis

MTCT of HIV-1 infection remains a significant problem in developing countries. Antiretroviral (ARV) prophylaxis can reduce the number of infections, but it does not eliminate the transmission risk. ARV efficacy is highly dependent on strict adherence to daily administration that is difficult to achieve for many women/babies. Even with optimal prophylaxis, infections occur at a rate of 1 to 5% at 6 months of age in infants of HIV-1 infected mothers who breastfeed [157]. Additional interventions that ideally do not rely on daily adherence to prevent transmission during prolonged breastfeeding need to be identified [158]. The use of an anti-HIV-1 passive immunization approach in addition to ARV prophylaxis could provide additional protection and deserves to be explored.

Passive immunization experiments of rhesus macaques have proven that NAbs can protect from MTCT. In humans, there are only 2 phase III studies of passive immunization to prevent MTCT that have been conducted. Both used polyclonal hyperimmune globulin preparations from HIV-1-infected donors. The first study was conducted in 1993–1997 in the United States in a non-breastfeeding population of HIV-1 infected pregnant women receiving zidovudine prophylaxis [159]. The second was conducted in 2004–2006 in Uganda in breastfeeding pregnant mothers receiving single-dose nevirapine [160]. Although the infusion of HIV hyperimmune preparations was proven to be safe, no additional benefit of these polyclonal preparations compared to antiretroviral treatment alone was shown in these two studies. However, it may be possible that polyclonal preparations did not contain enough NAbs specificities able to provide sterilizing immunity. The use of HuMoNAbs may be more appropriate to reach this goal and it was proposed to use them in human clinical trials [161,162]. However, several of the first-generation antibodies (b12, 2F5 and 2G12) were found ineffective or only partly effective against non-B viruses, particularly toward a panel of clade C Env-pseudotyped viruses derived from primary isolates of South African infected children and consequently did not seem to be relevant to prevent MTCT in populations where non-B viruses predominate [163]. In contrast, the second-generation of broadly HuMoNAbs directed against quaternary epitopes (PG9, PG16), the CD4bs epitopes (VRC01, NIH45-465G4W) and V3 glycan-dependent epitopes (PGT121, PGT128) were recently found to be able to neutralize most of HIV-1 non-B variants transmitted through breastfeeding [89,164–166].

Similarly, by comparing functional properties of CRF01-AE variants transmitted perinatally to infants with those of their chronically infected mothers, we recently found that all the transmitted variants were highly sensitive to both PG9 and PG16, significantly more sensitive than the maternal variants [95]. Together, these data would suggest that this new generation of HuMoNAbs could be efficient in passive immunization strategies. HIV prevention trials in African breastfed infants using the antibody HuMoNAb VRC01 are currently considered [167].

Conclusions

There are strong evidences for a selective advantage of the HIV-1 variants that are transmitted from the mother to the infant in the presence of maternal HIV-1-specific antibodies. An association between presence or titers of NAbs toward different HIV-1 strains and a lower rate of mother-to-child transmission has been found in several studies, suggesting that some NAbs could contribute to protection toward neonatal infection. Together, these data suggest that some neutralizing specificities might be protective and, in case of transmission, that the transmitted variants escape these specificities. Dissecting the antibody specificities that mediate protection toward MTCT of HIV-1 could provide important clues for identification of correlates of protection that would be useful for vaccine development. Experiments of passive immunization in newborn macaques have shown that first-generation HuMoNAbs can fully protect against SHIV infection, providing additional proof that NAbs can inhibit MTCT. The recent identification of highly potent second-generation HuMoNAbs provides a new opportunity to evaluate the efficacy of passive immunization to prevent mother-to-child transmission of HIV-1.

Abbreviations

NAbs: Neutralizing antibodies; MTCT: Mother-to-child transmission; HuMoNAbs: Human monoclonal neutralizing antibodies; HIV: Human immunodeficiency virus; PNGS: Potential N-linked glycosylation site; MPER: Membrane-proximal external region; CD4bs: CD4 binding site; ADCC: Antibody-dependent cellular cytotoxicity; SHIV: Simian-human immunodeficiency virus; TCLA virus: T-cell line laboratory-adapted virus; ARV: Antiretroviral.
Compe ning interests

The authors declare no competing interests.

Authors’ contributions

MB and FB wrote the manuscript. All authors read and approve the final manuscript.

Acknowledgments

Work on MCTC and NABs in the laboratory was supported by the Agence Nationale de Recherches sur le SIDA et les hépatites (ANRS, Paris, France) and by Sidaction (Paris, France).

Author details

1 Université François-Rabelais, UFR Médecine, Inserm U966 10 bld Tonnellé, cedex, 37032 Tours, France. 2 Centre National de Référence VH, Laboratoire de Bactériologie-Virologie, CHU Bretonneau, Tours, France.

Received: 7 August 2013 Accepted: 10 September 2013

References

1. Van Rompay KK, Berardi CJ, Dillard-Telm S, Tarara RP, Canfield DR, Valverde J, Acrivos P, Cutting JM, Tu-F熟练 CK, Boyer O, Grimm K, Starke-Hall C, Ni A, et al. Human neutralizing monoclonal antibodies against vaginal and mucosal HIV-1 infection. AIDS 2001, 15:663–671.

2. Ferrantelli F, Hofmann-Lehmann R, Rasmussen RA, Wang T, Xu W, Li PL, et al. Prevention of mucosal HIV-1 infection in macaques. J Infect Dis 2000, 182:720–724.

3. Berson LA, Lewis MG, NCHVI, CDC, USA. Neutralizing antibodies administered before, but not after, virulent SHIV prevented infection in macaques. AIDS Res Hum Retroviruses 1998, 14:1035–1043.

4. Baba TW, Liska V, Hofmann-Lehmann R, Vlasak J, Xu W, Ayehunie S, Cavacini LA, Posner MR, Katinger H, Stiegler G, et al. Neutralizing antibodies administered before, but not after, virulent SHIV prevented infection in macaques. AIDS Res Hum Retroviruses 1998, 14:1035–1043.

5. Mascola JR, Lewis MG, VanCott TC, Tyler AM, Posner MR, Katinger H, Stiegler G, et al. Neutralizing antibodies administered before, but not after, virulent SHIV prevented infection in macaques. AIDS Res Hum Retroviruses 1998, 14:1035–1043.

6. Ferrantelli F, Hofmann-Lehmann R, Rasmussen RA, Wang T, Xu W, Li PL, et al. Prevention of mucosal HIV-1 infection in macaques. J Infect Dis 2000, 182:720–724.

7. Hessel AI, Hangartner L, Hunter M, Haverne C, Beurskens FJ, Bakker JM, et al. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. J Infect Dis 2009, 200:589–598.

8. Hessel AI, Hangartner L, Hunter M, Haverne C, Beurskens FJ, Bakker JM, et al. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. J Infect Dis 2009, 200:589–598.

9. Hessel AI, Hangartner L, Hunter M, Haverne C, Beurskens FJ, Bakker JM, et al. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. J Infect Dis 2009, 200:589–598.

10. Hessel AI, Hangartner L, Hunter M, Haverne C, Beurskens FJ, Bakker JM, et al. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. J Infect Dis 2009, 200:589–598.

11. Hessel AI, Hangartner L, Hunter M, Haverne C, Beurskens FJ, Bakker JM, et al. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. J Infect Dis 2009, 200:589–598.

12. Hessel AI, Hangartner L, Hunter M, Haverne C, Beurskens FJ, Bakker JM, et al. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. J Infect Dis 2009, 200:589–598.

13. Hessel AI, Hangartner L, Hunter M, Haverne C, Beurskens FJ, Bakker JM, et al. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. J Infect Dis 2009, 200:589–598.
neatization-sensitive HIV-1 after heterosexual transmission. Science 2004, 303:2019–2022.
56. Gottlieb GS, Heath L, Nickle DC, Wong KG, Leach SE, Jacobs B, Gezahegne S, van’t Wout AB, Jacobson LP, Margolick JB, Mullins JJ: HIV-1 variation before seroconversion in men who have sex with men: analysis of acute/early HIV infection in the multicenter AIDS cohort study. J Infect Dis 2008, 197:1011–1015.
57. Lean GH, Muthui D, Brodie SJ, Zhu T, Diem K, Mullins JI, Corey L: Virus population homogenization following acute human immunodeficiency virus type 1 infection. J Virol 2002, 76:11953–11959.
58. Long EM, Martin HL Jr, Kreis JK, Rainwater SM, Lawres Y, Jackson DJ, Rekwar J, Mandalya K, Overbaugh J: Gender differences in HIV-1 diversity at time of infection. Nat Med 2000, 6:71–75.
59. Poss M, Martin HL, Kreis JK, Granville L, Chohan B, Nyangane P, Mandalya K, Overbaugh J: Diversity in virus populations from genital secretions and peripheral blood from women recently infected with human immunodeficiency virus type 1. J Virol 1995, 69:8118–8122.
60. Wolfs TF, Zwart G, Bakker M, Goudsmit J: HIV-1 genomic RNA diversification following sexual and parenteral virus transmission. Virology 1992, 189:103–110.
61. Wolinsky SM, Wike CM, Korber BT, Hutto C, Parks WP, Rosenblum LL, Kunstman KU, Furtado MR, Munoz J: Selective transmission of human immunodeficiency virus type 1 variants from mothers to infants. Science 1992, 255:1134–1137.
62. Zhu T, Mo H, Wang N, Nam DS, Cao Y, Koup RA, Ho DD: Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science 1993, 261:1179–1181.
63. Keeffe BF, Giorgi EE, Salazar-Gonzalez JF, Decker DM, Pham KT, Salazar MG, Sun C, Grayson T, Wang S, Li H, et al: Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci USA 2008, 105:7552–7557.
64. Li H, Bar KJ, Wang S, Decker JM, Chen S, Sun C, Salazar-Gonzalez JF, Salazar MG, Lean GH, Morgan CJ, et al: High multiplicity infection by HIV-1 in Men Who have Sex with Men. PLoS Pathog 2010, 6:e1000890.
65. Bar KJ, Li H, Chamberland A, Tremblay C, Routy JP, Grayson T, Sun C, Wang S, Lean GH, Morgan CJ, et al: Wide variation in the multiplicity of HIV-1 infection among injection drug users. J Virol 2010, 84:6241–6247.
66. Abrahams MR, Anderson JA, Giorgi EE, Seaighe C, Milions C, Feng LH, Atthaya GS, Treurnicht FK, Keele BF, Wood N, et al: Quantitating the multiplicity of infection with human immunodeficiency virus subtype C reveals a non-poisson distribution of transmitted variants. J Virol 2009, 83:3556–3567.
67. Haaland RE, Hawkins PA, Salazar-Gonzalez J, Johnson A, Tichacek A, Karita E, Manigat O, Mulenga J, Keele BF, Shaw GM, et al: Inflammatory genital infections mitigate a severe genetic bottleneck in heterosexual transmission of subtype A and C HIV-1. PLoS Pathog 2009, 5:e1000274.
68. Wike CM, Korber BT, Daniels MR, Hutto C, Munoz J, Furtado M, Parks W, Saah A, Bulters M, Kurawiwe JB, et al: HIV-1 sequence variation between isolates from mother-infant transmission pairs. AIDS Res Hum Retroviruses 1992, 8:1297–1300.
69. Scarlatti G, Leitner T, Halapi E, Wahlberg J, Marchisio P, Clerici-Schoeller MA, Wigzell H, Fenyo EM, Albert J, Uhlen M, et al: Comparison of variable region 3 sequences of human immunodeficiency virus type 1 from infected children with the RNA and DNA sequences of the virus populations of their mothers. Proc Natl Acad Sci USA 1993, 90:1721–1725.
70. Mulder-Kampinga GA, Kuiken C, Dekker J, Scherpber HJ, Boer K, Goudsmit J: Genomic human immunodeficiency virus type 1 RNA variation in mother and child following intra-uterine virus transmission. J Gen Virol 1993, 74:1747–1756.
71. van’t Wout AB, Kootstra NA, Mulder-Kampinga GA, Albrecht-van Lent N, Scherpber HJ, Veenstra J, Boer K, Coutinho RA, Miedema F, Schuttenaker H: Macrophage-tropic variants initiate human immunodeficiency virus type 1 infection after sexual, parenteral, and vertical transmission. J Clin Invest 1994, 94:2060–2067.
72. Lamers SL, Seeaman JW, We JX, Barrie KA, Pomroy M, Barrett DJ, Goodenow MM: Persistence of multiple maternal genotypes of human immunodeficiency virus type 1 in infants infected by vertical transmission. J Clin Infect Dis 1994, 33:380–390.
73. Ahmad N, Baroudy BM, Baker RC, Chappie C: Genetic analysis of human immunodeficiency virus type 1 envelope V3 region isolates from mothers and infants after perinatal transmission. J Virol 1995, 69:1001–1012.
74. Briant L, Wade CM, Puel J, Brown AJ, Guvader M. Analysis of envelope sequence variants suggests multiple mechanisms of mother-to-child transmission of human immunodeficiency virus type 1. J Virol 1995, 69:3778–3788.

75. Pasquier C, Cayrou C, Blancher A, Tourne-Petheil C, Berrebi A, Tricoire J, Puel J, Izopet J. Molecular evidence for mother-to-child transmission of multiple variants by analysis of RNA and DNA sequences of human immunodeficiency virus type 1. J Virol 1998, 72:4893–4850.

76. Sutthent R, Foongladda S, Chearskul S, Wanprapa N, Likanonskul S, Kostanont U, Rienrogpitak S, Sahaphong S, Wasi C. V3 Sequence diversity of HIV-1 subtype E in infected mothers and their infants. J Acquir Immune Defic Syndr Hum Retroviral 1998, 18:332–331.

77. Dickover RE, Garratty EM, Pfeuger S, Bryson VJ. Perinatal transmission of major, minor, and multiple maternal human immunodeficiency virus type 1 variants in utero and intrapartum. J Virol 2001, 75:2194–2203.

78. Zhang H, Orti G, Du Q, He J, Kankasa C, Bhat G, Wood C. Phylogenetic and phenotypic analysis of HIV type 1 env gp120 in cases of subtype C mother-to-child transmission. AIDS Res Hum Retroviruses 2002, 18:1415–1423.

79. Verhofstede C, Demecheleer E, De Cabooter N, Gaillard P, Mwanyumba F, de Clercq E, Verhoest P, Debyser Z, Vennoot C. Selection for human immunodeficiency virus type 1 (HIV-1) envelope sequence variants associated with mother-to-child transmission. J Virol 2003, 77:3050–3057.

80. Wu X, Parast AB, Richardson BA, Nduati R, John-Stewart G, Mbori-Ngacha D, Moore PL, Gray ES, Wibmer CK, Bhiman JN, Nonyane M, Sheward DJ, Herrmanas T, Bajma MR, Tabum NL, Abraham MR. Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape. Nat Med 2012, 18:1688–1692.

81. Moore PL, Gray ES, Wibmer CK, Bhiman JN, Nonyane M, Sheward DJ, Herrmanas T, Bajma MR, Tabum NL, Abraham MR. Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape. Nat Med 2012, 18:1688–1692.

82. Hoffmann FG, He X, West JT, Lemey P, Kankasa C, Wood C. Genetic variation in mother-child acute seroconversion pairs from Zambia. AIDS 2008, 22:817–824.

83. Hoffmann FG, He X, West JT, Lemey P, Kankasa C, Wood C. Genetic variation in mother-child acute seroconversion pairs from Zambia. AIDS 2008, 22:817–824.

84. Kielk W, Tully DC, Hoffmann FG, He X, Kankasa C, Wood C. Restricted genetic diversity of HIV-1 subtype C envelope glycoprotein from perinatally infected Zambian infants. PLoS One 2010, 5:e9294.

85. Kielk W, Tully DC, Hoffmann FG, He X, Kankasa C, Wood C. Restricted genetic diversity of HIV-1 subtype C envelope glycoprotein from perinatally infected Zambian infants. PLoS One 2010, 5:e9294.

86. Kielk W, Tully DC, Hoffmann FG, He X, Kankasa C, Wood C. Restricted genetic diversity of HIV-1 subtype C envelope glycoprotein from perinatally infected Zambian infants. PLoS One 2010, 5:e9294.

87. Kielk W, Tully DC, Hoffmann FG, He X, Kankasa C, Wood C. Restricted genetic diversity of HIV-1 subtype C envelope glycoprotein from perinatally infected Zambian infants. PLoS One 2010, 5:e9294.
neutralizing antibodies are not associated with a lower rate of mother-to-child transmission of HIV-1. J Virol 2012, 86:10540–10546.

110. Lynch JB, Nduati R, Bish CA, Richardson BA, Mabuka JM, Jalalian-Lechak Z, John-Stewart G, Overbaugh J. The breadth and potency of passively acquired human immunodeficiency virus type 1-specific neutralizing antibodies do not correlate with the risk of infant infection. J Virol 2011, 85:2525–2531.

111. Diomedes L, Nyoka S, Pastori C, Scotti L, Zambon A, Sherman G, Gray CM, Sarzotti-Kelsoe M, Lopalcio L. Passively transmitted gp41 antibodies in babies born from HIV-1 subtype C-seropositive women: correlation between fine specificity and protection. J Virol 2012, 86:4129–4138.

112. Walker LM, Simiek MD, Fiddy P, Gach JS, Wagner D, Zwick MB, Phogat SK, Poignard P, Burton DR. A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals. PLoS Pathog 2010, 6:e1001028.

113. Stamatatos L, Morris L, Burton DR, Mascola JR: Antibody responses in breast milk mirror those in plasma and are associated with neutralizing breadth from HIV-1-infected individuals. PLoS One 2010, 5:e8805.

114. Gray ES, Taylor N, Wycuff D, Moore PL, Tomaras GD, Wibmer CK, Puren A, Schmidt SD, Wu L, Xu L, et al. Rational design of envelope identifies a gp120 epitope recognized by a broadly reactive neutralizing human antibody. J Virol 2011, 85:9555–9567.

115. Mestecky J, Jackson S, Moldoveanu Z, Nesti LR, Kulhavy R, Prince SJ, Sabbaj S, Mulligan MJ, Geopfert PA. Paucity of antigen-specific IgA responses in sera and external secretions of HIV-1-infected individuals. AIDS Res Hum Retroviruses 1999, 15:1365–1376.

116. Van de Perre P. Transfer of antibody via mother’s milk. Vaccine 2003, 21:3374–3376.

117. Fouda GG, Yates NL, Pollara J, Shen X, Overman GR, Mahlokzeza T, Wilks AB, Kang HH, Salazar-Gonzalez JF, Salazar MG, et al: HIV-specific functional antibody responses in breast milk mirror those in plasma and are primarily mediated by IgG antibodies. J Virol 2011, 85:9555–9567.

118. Poignard P, Wilks AB, Bilinge EP, Kang HH, Mahlokzeza T, Coffey RT, Carville A, Letvin NL, Seaman MS: Limited contribution of mucosal IgA to simian immunodeficiency virus (SIV)-specific neutralizing antibody response and virus envelope evolution in breast milk of SIV-infected, lactating rhesus monkeys. J Virol 2010, 84:2009–2018.

119. Williams SB, Flanagan TP, Cu-Uvin S, Mayer K, Williams P, Ettore CA, Artzstein AW, Duer R, VanCott TC. Human immunodeficiency virus (HIV)-specific antibody in cervicovaginal lavage specimens obtained from women infected with HIV type 1. Clin Infect Dis 2002, 35:611–617.

120. Lu FX. Predominate HIV-1-specific IgG activity in various mucosal compartments of HIV-infected individuals. Clin Immunol 2000, 97:509–68.

121. Haimovici F, Mayer KH, Anderson DJ. Quantitation of HIV-1-specific IgG, IgA, and IgM antibodies in human genital tract secretions. J Acquir Immune Defic Syndr Hum Retrovirology 1997, 15:185–191.

122. Fiore JR, Laddavo D, Lepere A, La Grasta L, Di Stefano M, Saracino A, Lopalcio P, Pastore G, Angaranu G. Limited secretory-IgA response in cervicovaginal secretions from HIV-1 infected, but not high risk seronegative women: lack of correlation to genital viral shedding. New Microbiol 2000, 23:85–92.

123. Bellec L, Ghys PD, Hocini H, Nkengasong JN, Tranchot-Diallo J, Daillo MO, Etienne-Troare V, Maurice C, Becquet P, Matta M, et al: Cervicovaginal secretory antibodies to human immunodeficiency virus type 1 (HIV-1) that block viral transcytosis through tight epithelial barriers in highly exposed HIV-1-seronegative African women. J Infect Dis 2001, 184:1412–1422.

124. Rychter J, Amedee AM: The antibody response to SIV in lactating rhesus macaques. J Acquir Immune Defic Syndr 2005, 38:135–141.

125. Kuhn L, Trabattoni D, Kankasa C, Sinkila M, Lissiso F, Gisho M, Aidrovandi G, Thea D, Clerici M. HIV-specific secretory IgA in breast milk of HIV-positive mothers is not associated with protection against HIV transmission among breast-fed infants. J Pediatr 2005, 146:511–616.

126. Becquet P, Hocini H, Levy M, Sepou S, Katatzikine MD, Bellec L. Secretory anti-human immunodeficiency virus (HIV) antibodies in colostrum and breast milk are not a major determinant of the protection of early postnatal transmission of HIV. J Infect Dis 2000, 181:532–539.

127. Mabuka J, Nduati R, Odeo-Davii K, Peterson D, Overbaugh J. HIV-specific antibodies capable of ADCC are common in breastmilk and are associated with reduced risk of transmission in women with high viral loads. PLoS Pathog 2012, 8:e1002739.

128. Bomsel M, Tudor D, Drillet AS, Alfenis A, Gancor Y, Roger MG, Mornu Z, Arnacker M, Chalifour A, Diomedes L, et al: Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges. Immunity 2011, 34:269–280.

129. Watkins JD, Shukul AM, Muthiar WW, Siddappa NB, Lakshashe KS, Kim M, Reinherz EL, Gupta S, Forthal DN, Santenius OJ, et al: Anti-HIV IgA isotypes: differential virion capture and inhibition of transcytosis are linked to prevention of mucosal RS SHIV transmission. AIDS 2013, 27:12–20.

130. Roben P, Moore JP, Thali M, Sodroski J, Barbas CF 3rd, Burton DR: Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. J Virol 1994, 68:4821–4828.

131. Thali M, Oleshovsky U, Furman C, Gubaudo D, Posner M, Sodroski J. Characterization of a discontinuous human immunodeficiency virus type 1 gp120 epitope recognized by a broadly reactive neutralizing human monoclonal antibody. J Virol 1991, 65:6168–6193.

132. Trkola A, Parkiet M, Muster T, Ballaun C, Buchacher A, Sullivan N, Srinivasan K, Sodroski J, Moore JP, Katinger H. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol 1996, 70:1100–1108.

133. Muster T, Steindl F, Prantscher M, Trkola A, Kilima A, Himmiger M, Ruder K, Katinger H: A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol 1993, 67:6642–6647.

134. Zwick MB, Labrijn AF, Wang M, Spelenhauer C, Saphire EO, Binley JM, Moore JP, Stiegler G, Katinger H, Burton DR, Parren PW: Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol 2001, 75:10892–10905.

135. Li J, Lord CJ, Haseltine W, Letvin NL, Sodroski J: Infection of cynomolgus monkeys with a chimeric HIV-1/SIVmac virus that expresses the HIV-1 envelope glycoproteins. J Acquir Immune Defic Syndr 1992, 5:639–646.

136. Luciw PA, Pratt-Lowe E, Shaw KE, Levy JA, Cheng-Mayer C: Persistent infection of rhesus macaques with T-cell line-tropic and macrophage-tropic clones of simian/human immunodeficiency viruses (SHIV). Proc Natl Acad Sci USA 1995, 92:7490–7494.

137. Shibata R, Kawamura M, Sakai H, Hayami M, Ishimoto A, Adachi A. Generation of a chimeric human and simian immunodeficiency virus virus infection to monkey peripheral blood mononuclear cells. J Virol 2013, 87:3514–3520.

138. Sakuragi S, Shibata R, Mukai R, Komatsu T, Fukasawa M, Sakai J, Sakuragi J, Nakagomi O, Kato Y, Saphire EO, Binley JM, Moore JP, Stiegler G, Katinger H, Burton DR, Parren PW: Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol 2001, 75:10892–10905.
146. Shibata R, Mäklerell F, Siemon C, Matano T, Parta M, Miller G, Fredrickson T, Martin MA. Infection and pathogenicity of chimeric simian-human immunodeficiency viruses in macaques: determinants of high virus loads and CD4 cell killing. J Infect Dis 1997, 176:362–373.

147. Jayaraman P, Zhu T, Misher L, Mohan D, Keller L, Polacino P, Richardson BA, Bielefeldt-Ohmann H, Anderson D, Hu SL, Haigwood NL. Evidence for persistent, occult infection in neonatal macaques following perinatal transmission of simian-human immunodeficiency virus SF162P3. J Virol 2007, 81:832–834.

148. Hofmann-Lehmann R, Vasak J, Rasmussen RA, Smith BA, Baba TW, Wang T, Montefiori DC, McClure HM, Anderson DC, et al. Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus infection challenge. J Virol 2001, 75:7470–7480.

149. Hofmann-Lehmann R, Vasak J, Rasmussen RA, Jiang S, Li PL, Baba TW, Montefiori DC, Bernacky BJ, Rovi TA, Schmidt R, et al. Postnatal pre- and postexposure passive immunization strategies: protection of neonatal macaques against oral simian-human immunodeficiency virus infection challenge. J Med Primatol 2002, 31:109–119.

150. Ferrantelli F, Rasmussen RA, Buckley KA, Li PL, Wang T, Montefiori DC, Katinger H, Stiegler G, Anderson DC, McClure HM, Ruprecht RM. Complete protection of neonatal rhesus macaques against oral exposure to pathogenic simian-human immunodeficiency virus by human anti-HIV monoclonal antibodies. J Virol 2004, 88:2167–2173.

151. Ferrantelli F, Buckley KA, Rasmussen RA, Chalmers A, Wang T, Li PL, Williams AL, Hofmann-Lehmann R, Montefiori DC, Cavacini LA, et al. Time dependence of protective post-exposure prophylaxis with human monoclonal antibodies against pathogenic SHIV challenge in newborn macaques. Virology 2007, 358:69–78.

152. Huang J, Oloff G, Laub L, Louder MK, Doros-Rose NA, Longo NS, Immich H, Baker RT, Chakrabarti B, Sharma SK, et al. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 2012, 491:406–412.

153. Diskin R, Scheid JF, Marcovecho PM, West AP Jr, Klein F, Gao H, Gnanapragasam PN, Abadir A, Seaman MS, Nussenzweig MC, Bjorkman PJ. Increasing the potency and breadth of an HIV antibody by using structure-based rational design. Science 2011, 334:1289–1293.

154. Moldt B, Rakasz EG, Schultz N, Chen-Hui PY, Swiderek K, Weissgrau KL, Piaskowski SM, Bergman Z, Watkins DJ, Poignard P, Burton DR. Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo. Proc Natl Acad Sci USA 2012, 109:18921–18925.

155. Klein F, Halper-Stromberg A, Horwitz JA, Gruell H, Scheid JF, Boumazos S, Mouquet H, Spatz LA, Diskin R, Abadir A, et al. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature 2012, 492:118–122.

156. Ng CT, Jaworski JP, Jayaraman P, Sutton WF, Delo P, Keller L, Anderson D, Landucci G, Richardson BA, Burton DR, et al. Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques. Nat Med 2010, 16:117–119.

157. Shvetz AK, Maldonado Y. Antiretroviral drugs to prevent mother-to-child transmission of HIV during breastfeeding. Curr HIV Res 2013, 11:102–125.

158. Mofenson LM. Prevention of mother-to-child HIV transmission—why we still need a preventive HIV immunization strategy. J Acquir Immune Defic Syndr 2011, 58:359–362.

159. Stehml ER, Lambert JS, Mofenson LM, Bethel J, Whitehouse J, Nugent R, Maye J Jr, Glenn Fowler M, Mathison BJ, Reichelderfer P, et al. Efficacy of zidovudine and human immunodeficiency virus (HIV) hyperimmune immunoglobulin for reducing perinatal HIV transmission from HIV-infected women with advanced disease: results of pediatric AIDS clinical trials group protocol 185. J Infect Dis 1999, 179:567–575.

160. Onyango-Makumbi C, Ormer SB, Mubiru M, Mouton LH, Nakabito C, Mwesoke P, Mmrio F, Zwerksi S, Wizgerl H, Falskeveden L, et al. Safety and efficacy of HIV hyperimmune globulin for prevention of mother-to-child HIV transmission in HIV-1-infected pregnant women and their infants in Kampala, Uganda (HIVIGLOB/NVP STUDY). J Acquir Immune Defic Syndr 2011, 58:399–407.

161. Xu W, Hofmann-Lehmann R, McClure HM, Ruprecht RM. Passive immunization with human neutralizing monoclonal antibodies: correlates of protective immunity against HIV. Vaccine 2002, 20:1956–1960.

162. Safrit JT, Ruprecht R, Ferrantelli F, Xu W, Kitabwilla M, Van Rompay K, Mathias M, Haigwood N, Mascola JR, Luzuriaga K, et al. Immunoprophylaxis to prevent mother-to-child transmission of HIV-1. J Acquir Immune Defic Syndr 2004, 35:169–177.

163. Gray ES, Meyers T, Gray G, Montefiori DC, Morris L. Insensitivity of paediatric HIV-1 subtype C viruses to broadly neutralising monoclonal antibodies raised against subtype B. PLoS Med 2006, 3:e255.

164. Russell ES, Ojeda S, Foula GG, Meshnick SR, Montefiori D, Permar SR, Swanstrom R. Short communication: HIV type 1 subtype C variants transmitted through the bottleneck of breastfeeding are sensitive to new generation broadly neutralizing antibodies directed against quaternary and CD4-binding site epitopes. AIDS Res Hum Retroviruses 2013, 29:511–515.

165. Nakamura KJ, Cerino C, Sobiera ER, Heath L, Sirkala M, Kankasa C, Thea DM, Mullins JI, Kuhl L, Aldrovandi GM. Coverage of primary mother-to-child HIV transmission isolates by second-generation broadly neutralizing antibodies. AIDS 2013, 27:337–346.

166. Mabuka J, Goo L, Omeda MM, Nduati R, Overbaugh J. HIV-1 maternal and infant variants show similar sensitivity to broadly neutralizing antibodies, but sensitivity varies by subtype. AIDS 2013, 27:1535–1544.

167. Editorial: prevention measures. Nat Med 2013, 19:247.